Salactol Collodion

For the topical treatment of warts, verrucas, corns and calluses.

For adults, children and the elderly.

Salactol should be applied once daily usually at night. It can take up to twelve (12) weeks for resistant lesions to disappear, and it is necessary to persevere with the treatment.

Soak the affected site in warm water and pat dry. Gently rub the surface of the wart, verruca, corn or callus with a pumice stone or manicure emery board to remove any hard skin. Using the applicator provided, carefully apply a few drops of Salactol to the lesion, allowing each drop to dry before applying the next one. Take care to localise the application to the affected area. Plantar warts should be covered with an adhesive plaster. Leave for 24 hours. Repeat the procedure daily, after first removing any plaster.

Not to be used on or near the face, intertriginous or anogenital regions or by diabetics or individuals with impaired peripheral blood circulation.

Not to be used on moles, birthmarks, hairy warts or on any other skin lesions for which Salactol is not indicated.

Not to be used in cases of sensitivity to any of the ingredients.

Keep away from the eyes and mucous membranes.

The gel should be applied carefully to the wart, verruca, corn or callus only to avoid possible irritation of surrounding normal skin.

Some mild, transient irritation may be expected, but in cases of more severe or persistent pain/irritation, the treatment should be suspended and/or discontinued. See also Section 4.8.

Extremely flammable.

Avoid spillage.

Avoid inhaling vapour.

Replace cap tightly alter use.

None known

There are no or limited amount of data from the use of Salactol Collodion during pregnancy.

Salactol Collodion should not be used during pregnancy, except for short-term treatment of a small single wart, verruca, corn or callus.

It is not known if the systemic Salactol Collodion exposure reached after topical administration can be harmful to an embryo/fetus.

During the third trimester of pregnancy, systemic use of prostaglandin synthetase inhibitors may induce cardiopulmonary and renal toxicity in the fetus. At the end of the pregnancy prolonged bleeding time in both mother and child may occur, and labour can be delayed.

None known.

Salactol may be irritant in certain patients, which in rare instances may appear as a temporary blemish on the skin. See also Section 4.4.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Any excessive use of Salactol could cause irritation of the skin. If this occurs, Salactol should be used more sparingly or applied less frequently.

Accidental oral ingestion should be treated immediately by gastric lavage with a 2 to 5% aqueous sodium bicarbonate solution. Fluid and electrolyte balance should be monitored and appropriate supportive measures should be provided. Symptoms include headache, nausea, vomiting, diarrhoea and respiratoty depression.

The combination of salicylic acid and lactic acid in flexible collodion has been shown to be particularly efficacious in treating warts, verrucas, corns and calluses.

Salicylic acid has bacteriostatic and fungicidal actions as well as keratolytic properties. Its effectiveness for topical treatment of hyperkeratotic skin lesions is based on mild keratolytic action which produces slow and painless destruction of the epithelium. In the treatment of warts, a mild irritant reaction, which may render the virus more prone to immunologic stimulation or response, may add to the mechanical removal of infected cells. Apart from its antiseptic and caustic properties, lactic acid enhances the availability of salicylic acid from the dried collodion.

Salactol contains 16.7% salicylic acid and 16.7% lactic acid in flexible collodion. The bioavailability of salicylic acid is reduced as the collodion film dries on the skin due to entrapment of the drug which inhibits release. The addition of lactic acid to salicylic acid collodion provides more efficient release of the salicylic acid, since the non-volatile lactic acid remains in the film, thus permitting continued release of the keratolytic which may otherwise be entrapped within the dried collodion film. Systemic absorption of salicylic acid or lactic acid after application to small circumscribed areas is exceedingly unlikely.

None stated.

Pyroxylin (contains isopropyl alcohol as a damping solvent)

Colophony

Caster oil

Industrial Methylated Spirit '66 OP'

Ether

None known.

36 months in unopened container, 3 months in opened container.

Do not store above 25 °C.

10 ml amber glass bottle with HDPE cap, incorporating a specially designed spatula for ease of application.

This is supplied as an original pack (OP).

Not applicable